Federal Antitrust Lawsuit Against Major Health Insurers Advances
A significant antitrust lawsuit involving some of the largest U.S. health insurers has progressed, with a federal judge allowing the case to proceed. On March 30, 2026, the U.S. District Court for the District of Massachusetts rejected a motion to dismiss from defendants including Zelis Healthcare and insurers Aetna, The Cigna Group, Elevance Health Companies, Humana, and UnitedHealth Group.
The lawsuit, initiated by a consortium of healthcare providers nationwide, accuses the insurers and Zelis, a healthcare technology firm specializing in network management and payment solutions, of collaborating to reduce out-of-network provider payments. The case highlights two key repricing tools by Zelis—the Established Reimbursement Solution and Reference Based Pricing—which the providers claim lead to undervaluing claims based on in-network data that may not fully reflect market conditions.
Providers allege that these practices force them to accept lower reimbursements or engage in ineffective negotiations. One specific complaint notes that Pacific Inpatient Medical Group had a claim repriced at an 88% discount. The plaintiffs assert that these practices severely impact their revenue, sometimes cutting it by half, while consumers do not benefit from reduced premiums despite the lower payments.
The insurers' request for dismissal argued a lack of standing and questioned the direct impact of repricing tools on providers. Although the insurers posited that providers could negotiate or directly charge patients, the court upheld that the plaintiffs’ inability to negotiate effectively, coupled with prohibitions on balance billing, established grounds for harm under antitrust laws.
The court dismissed the insurers' argument that the practice merely lowers healthcare costs, noting that price suppression orchestrated by dominant market players can lead to antitrust injuries for suppliers, even if consumers indirectly benefit. Allegations of conspiracy are central to the case, with claims of both horizontal and hub-and-spoke conspiracies. The former suggests that Zelis and insurers collude in the out-of-network services market, while the latter views Zelis as a central facilitator with insurers acting as spokes.
Supporting evidence presented includes the adoption of Zelis's tools by competing insurers and shared claim data that could lead to coordinated pricing strategies. The court found the defined market of out-of-network services valid for the lawsuit, despite the defendants' objections over its scope. Additionally, Humana's cessation of selling the contested health products in 2024 did not exempt it from allegations related to earlier participation in the alleged scheme.
In separate litigation developments, Aetna, UnitedHealth, and Elevance successfully motioned to arbitrate certain claims, which the court has stayed pending resolution. This case now moves into the discovery phase, where the insurers must substantiate their cost-management defenses against claims of anti-competitive behavior. The outcome could have significant implications for the insurance industry's approach to out-of-network repricing strategies.